Company news
Racura Oncology Ltd (ASX:RAC) news
Racura Oncology Ltd news releases on 6ix. Latest, Nov 14, 2019: Race reveals new strategy for cancer drug Bisantrene
Press releases — page 4
Race reveals new strategy for cancer drug Bisantrene
November 14, 2019
Appendix 4C - quarterly
October 17, 2019
Prominent biotech investor leads investment in Race
August 19, 2019
First patient treated in Bisantrene trial in Israel
July 24, 2019
Bisantrene AML trial to start in Israel
May 13, 2019
Bisantrene IND Update
April 24, 2019
Race files Bisantrene IND with FDA
March 24, 2019
Principal Investigator appointed for Bisantrene
February 24, 2019
Race Receives $228k R&D Tax Incentive Refund
January 31, 2019
Race appoints leading haematologist to support Bisantrene
January 21, 2019
Race signs agreement for Bisantrene NPP in Israel
December 16, 2018
Race appoints Biosynergy to pursue Bisantrene licensing
October 31, 2018
September 2018 Quarterly Report
October 25, 2018
Appendix 4E & Financial Statements
August 21, 2018
June 2018 Quarterly Report
July 26, 2018
FDA Grants Bisantrene Rare Paediatric Disease Designation
July 18, 2018
Bisantrene poster presented at French Leukaemia Conference
June 26, 2018
Bisantrene approval in UK for supply as unlicensed medicine
June 21, 2018
RAC cancer drug success in AML reported by French doctors
June 4, 2018
Race executes agreement for Bisantrene clinical trial
May 14, 2018
Race signs global distribution agreement with Durbin PLC
April 10, 2018
Race increases placement to $3.69m
March 16, 2018
Race completes over-subscribed $3.159 million placement
March 11, 2018
Second Bisantrene Patent Allowed in US
February 20, 2018
Notice of Allowance for Bisantrene Patent in US
January 28, 2018
Race Receives $170k R&D Tax Incentive Refund
January 24, 2018
Race Oncology Produces First Batch of Bisantrene
September 11, 2017
Appendix 4E & Annual Financial Statements
August 29, 2017
Issue of Options
August 13, 2017
Peer-Reviewed The Rediscovery of Bisantrene Published
July 19, 2017
Race Completes Over-Subscribed $2.5 Million Placement
July 16, 2017
Race Joint Venture with TargImmune
July 10, 2017
Race Announces NCI Collaboration
July 4, 2017
Bisantrene License Agreement for Korea
March 26, 2017
Pre-IND Meeting Confirms 505(b)(2) Pathway for Bisantrene
February 15, 2017
Race Oncology Update & Investor Presentation
January 10, 2017
Race Signs Agreement with US Based IriSys LLC
October 24, 2016
Race Signs Key Manufacturing Agreement for Bisantrene
October 4, 2016
Race Signs NPP Partnership with CarthaGenetics in Europe
September 4, 2016
Race signs agreement with Camargo Pharmaceutical
July 25, 2016
Race signs agreement with Crystal Pharmatech
July 24, 2016
Admission to Official List
July 11, 2016